COVID-19: Analysis of the Emerging Disease Landscape - March 2020
Summary
The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.
Reasons to Buy
- Global epidemiology metrics and trends
- Snapshot of epidemiological trends to date in the top three most-affected countries
- An overview of the pipeline for antivirals and vaccines
- Summary of available efficacy data
- An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- Highlights in deal-making trends, particularly public-private partnerships
- Spotlight on social media coverage
Table of Contents
1 Executive Summary
2 Epidemiology
3 Pipeline Overview
4 Pipeline Overview
5 Clinical Trials
6 Deal-making Trends
7 Social Media Trends
8 Key Findings
9 Appendix
10 About the Publisher
